Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop

Executive Summary

Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints

You may also be interested in...



Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4

Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4

Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says

An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS042828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel